mRNA-1647 is a vaccine candidate combining six mRNAs in a single vial, which encode for two antigens on the surface of CMV: five mRNAs encoding the subunits that form the membrane-bound pentamer complex and one mRNA encoding the full-length membrane-bound glycoprotein B (gB)
mRNA-1647 is designed to produce an immune response against both the pentamer and gB for the prevention of CMV infection.
Studies are on-going to determine the proper dosage
September 9, 2019: Moderna Announces Positive Interim Results from Phase 1 Cytomegalovirus (CMV) Vaccine (mRNA-1647) Study and Progress Toward Phase 2 and Pivotal Trials
Clinical Trial NCT03382405: Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults